Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS)

Annals of Internal Medicine

Volumn 125, Issue 8, 1996, Pages 680-687

  Bone, Roger C ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; REVIEW; SYNDROME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; IMMUNE TOLERANCE; MULTIPLE ORGAN FAILURE; SYNDROME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0030587937     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-8-199610150-00009     Document Type: Article

References (101)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319-23.
2. Petty TL, Ashbaugh DG. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. Chest. 1971;60:233-9.
3. Baue AE. Multiple, progressive, or sequential systems failure. A syndrome of the 1970s. Arch Surg. 1975;110:779-81.
4. Skillman JJ, Bushnell LS, Hedley-Whyte J. Peritonitis and respiratory failure after abdominal operations. Ann Surg, 1969;170:122-7.
5. Burke JF, Pontoppidan H, Welch CE. Mgh output respiratory failure. Ann Surg. 1963;158:581-95.
6. Clowes GH Jr, Zuschneid W, Tumer M, Blackburn G, Rubin J, Toala P, et al. Observations on the pathogenesis of the pneumonitis associated with severe infections in other parts of the body. Ann Surg. 1968;167:630-50.
7. Tilney NL, Bailey GL, Morgan AP. Sequential system failure after rupture of abdominal aortic aneurysms: an unsolved problem in postoperative care. Ann Surg. 1973;178:117-22.
8. Border JR, Chenier R, McManamy RH, La Duca J, Seibel R, Birkhahn R, et al. Multiple systems organ failure: muscle fuel deficit with visceral protein malnutrition. Surg Clin North Am. 1976;56:1147-67.
9. Polk HC Jr, Shields CL. Remote organ failure: a valid sign of occult intraabdominal infection. Surgery. 1977;81:310-3.
10. Eiseman B, Beart R, Norton L. Multiple organ failure. Surg Gynecol Obstet. 1977;144:323-6.
11. Fry DE, Pearlstein L, Fulton RL, Polk HC Jr. Multiple system organ failure. The role of uncontrolled infection. Arch Surg. 1980;115:136-40.
12. Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120: 1109-15.
13. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of gram-negative bacteremia and shock with human anti-serum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225-30.
14. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457-69.
15. McCutchan JA, Wolff JL, Ziegler EJ, Braude AI. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteria, gram-negative infection in patients with prolonged neutropenia. Schweiz Med Wochenschr Suppl. 1983;14:40-5.
16. Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, van Melle G, Klauber MR, et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985;2:59-63.
17. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 Study Group. J Infect Dis. 1992;165:695-701.
18. Calandra T, Glauser MP, Schellekens J, Verhoef J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prosoective, double-blind randomized trial. J Infect Dis. 1988;158:312-9.
19. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. The Intravenous Immunoglobulin Collaborative Study Group. N Engl J Med. 1992;327:234-40.
20. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991;266:1097-102.
21. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med. 1996;23:994-1006.
22. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. N Engl J Med. 1991;324:429-36.
23. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-IA. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med. 1994;121:1-5.
24. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med. 1987;317:659-65.
25. Bone RC, Fisher CJ Jr, Clemmer TP, Slotrnan GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-8.
26. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273:934.
27. Fisher CJ Jr, Dhaihaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271:1836-44.
28. Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med. 1994;22: 1720-8.
29. Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Letulzo Y, Radennacher P, et al. Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe gram-negative sepsis [Abstract]. Am J Respir Crit Care Med. 1995;151:A447.
30. Freeman BD, Natanson C. Clinical trials in sepsis and septic shock in 1994 and 1995. Current Opinion in Critical Care. 1995;1:349-57.
31. Tran DD, Groeneveld AB, van der Meulen J, Nauta JJ, Strack van Schijndel RJ, Thijs LG. Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med. 1990;18: 474-9.
32. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638-52.
33. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
34. Zuckerman SH, Bendele AM. Regulation of serum tumor necrosis factor in glucocorticoid-sensitive and -resistant rodent endotoxin shock models. Infect Immun. 1989;57:3009-13.
35. Balk RA, Jacobs RF, Tryka AF, Townsend JW, Walls RC, Bone RC. Effect of ibuprofen on neutrophil function and acute lung injury in canine endotoxin shock. Crit Care Med. 1988;16:1121-7.
36. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-7.
37. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88:1747-54.
38. Keogh C, Fong Y, Marano MA, Seniuk S, He W, Barber A, et al. Identification of a novel tumor necrosis factor a/cachectin from the livers of burned and infected rats. Arch Surg. 1990;125:79-85.
39. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269: 1829-35.
40. Remick DG. Applied molecular biology of sepsis. J Crit Care. 1995;10:198-212.
41. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24:163-72.
42. Moore FA, Moore EE, Read RA. Postinjury multiple organ failure: role of extrathoracic injury and sepsis in adult respiratory distress syndrome. New Horiz. 1993;1:538-49.
43. Strieter RM, Kunkel SL, Bone RC. The role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993;21(10 Suppl):S447-63.
44. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol. 1995;7:517-23.
45. Fukushima R, Alexander JW, Gianotti L, Ogle CK. Isolated pulmonary infection acts as a source of systemic tumor necrosis factor. Crit Care Med. 1994;22:114-20.
46. Ford HR, Hoffman RA, Wing EJ, Magee DM, McIntyre L, Simmons RL. Characterization of wound cytokines in the sponge matrix model. Arch Surg. 1989;124:1422-8.
47. Meduri GU, Kohler G, Headley S, Tolley F, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts a poor outcome. Chest. 1995;108:1303-14.
48. Sauder DN, Semple J, Truscott D, George B, Clowes GH. Simulation of muscle protein degradation by murine and human epidermal cytokines: relationship to thermal injury. J Invest Dermatol. 1986;87:711-4.
49. Kupper TS, Deltch EA, Baker CC, Wong WC. The human bum wound as a primary source of interleukin-1 activity. Surgery. 1986;100:409-15.
50. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Pattern of cytokine expression in community-acquired pneumonia. Chest. 1995;107:1342-9.
51. Wang P, Ba ZF, Morrison MH, Ayala A, Dean RE, Chaudry IH. Mechanism of the beneficial effects of ATP-MgC12 following trauma-hemorrhage and resuscitation: downregulation of inflammatory cytokine (TNF, IL-6) release. J Surg Res. 1992;52:364-71.
52. Wang P, Ba ZF, Morrison MH, Ayala A, Chaudry IH. Mechanism of the beneficial effects of pentoxifylline on hepatocellular function after trauma hemorrhage and resuscitation. Surgery. 1992;112:451-7.
53. Tracey KJ, Lowry SF, Cerami A. Cachectin/TNF-alpha in septic shock and septic adult respiratory distress syndrome [Editorial]. Am Rev Respir Dis. 1988;138:1377-9.
54. Stephens KE, Ishizaka A, Larrick JW, Raffin TA. Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. Am Rev Respir Dis. 1988;137:1364-70.
55. Ibbotson GC, Wallace JL. Beneficial effects of prostaglandin E2 in endotoxin shock are unrelated to effects on PAF-acether synthesis. Prostaglandins. 1989;37:237-50.
56. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645-55.
57. Petrak RA, Balk RA, Bone RC. Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthesis inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin. 1989;5:303-14.
58. Sigurdsson GH, Christenson JT, el-Rakshy MB, Sadek S. Intestinal platelet trapping after traumatic and septic shock. An early sign of sepsis and multiorgan failure in critically ill patients? JAMA. 1992;20:458-67.
59. Cipolle MD, Pasquale MD, Cerra FB. Secondary organ dysfunction. From clinical perspectives to molecular mediators. Crit Care Clin. 1993;9:261-98.
60. Rinaldo JE, Gorry M, Strieter R, Cowan H, Abdolrasulnia R, Shepherd V. Effect of endotoxin-induced cell injury on 70-kD heat shock proteins in bovine lung endothelial cells. Am J Respir Cell Mol Biol. 1990;3:207-16.
61. Levi M, ten Cate H, van der Poll T, van Deventer SJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA. 1993;270:975-9.
62. Gomez-Jimenez J, Salgado A, Mourelle M, Martin MC, Segura RM, Peracaula R, et al. L-arginine: nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med. 1995;23:253-8.
63. Miyauchi T, Tomobe Y, Shiba R, Uhikawa T, Yanagisawa M, Kimura S, et al. Involvement of endothelin in the regulation of human vascular tonus. Potent vasoconstrictor effect and existence in endothelial cells. Circulation, 1990;81:1874-80.
64. Miller-Graziano CL, Szabo G, Kodys K, Griffey K. Aberrations in posttrauma monocyte (MO subpopulation: role in septic shock syndrome J Trauma. 1990;30(12 Suppl):S86-96.
65. Randow F, Syrbe U, Meisel C, Krausen D, Zuckermann H, Platzer C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med. 1995;181:1887-92.
66. Syrbe U, Meinecke A, Platzer C, Makki A, Asadullah K, Klug C, et al. Improvement of monocyte function - a new therapeutic approach? In: Reinhart K, Eyrich K, Sprung CL, eds. Sepsis: Current Perspectives in Pathophysiology and Therapy. Berlin: Springer-Verlag; 1994:473-500.
67. Mills CD, Caldwell MD, Gann DS. Evidence of a plasma-mediated "window" of immunodeficiency in rats following trauma. J Clin Immunol. 1989; 9:139-50.
68. Bone RC. Why the sepsis trials failed. JAMA. 1996;276:7.
69. Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC Jr. Depressed interferon-γ production and monocyte HLA-DR expression after severe injury. Arch Surg. 1988;123:1309-13.
70. Cheadle WG, Hershman MJ, Wellhausen SR, Polk HC. Role of monocytic HLA-DR expression following trauma in predicting clinical outcome. In: Faist E, Ninnemann J, Green D, eds. Immune Consequences of Trauma, Shock and Sepsis. Berlin: Springer-Verlag; 1989:119-22.
71. Gibbons RA, Martinez OM, Lim RC, Horn JK, Garovoy MR. Reduction in HLA-DR, HLA-DQ, and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury. Clin Exp Immunol. 1989; 75:371-5.
72. Wakefield CH, Carey PD, Foulds S, Monson JR, Guillou PJ. Changes in major histocompatibility complex class Il expression in monocytes and T cells of patients developing infection after surgery. Br J Surg. 1993;80:205-9.
73. Browder W, Williams D, Pretus H, Olivero G, Enrichens F, Mao P, et al. Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg. 1990;211:605-12.
74. Hamilton G, Hofbauer S. Hamilton B. Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis. 1992;24:361-8.
75. Faist E, Storck M, Hultner L, Redl H, Ertel W, Walz A, et al. Functional analysis of monocyte activity through synthesis patterns of proinflammatory cytokines and neopterin in patients in surgical intensive care. Surgery. 1992; 112:562-72
76. Rothe G, Oser A, Valet G. Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes. Naturwissenschaften 1988;75:354-6.
77. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915-24.
78. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med. 1987;166:571-6.
79. Czarniecki CW, Chiu HH, Wong GH, McCabe SM, Palladino MA. Transforming growth factor-beta 1 modulates the expression of class 11 histocompatibility antigens on human cells. J Immunol. 1988;140:4217-23.
80. Chantry D, Turner M, Abney E, Feldmann M. Modulation of cytokine production by transforming growth factor-beta. J Immunol. 1989;142:4295-300.
81. Abraham E. Physiologic stress and cellular ischemia: relationship to immunosuppression and susceptibility to sepsis. Crit Care Med. 1991;19:613-8.
82. Ninnemann JL, Condie JT, Davis SE, Crockett RA. Isolation of immunosuppressive serum components following thermal injury. J Trauma. 1982;22: 837-44.
83. Christou NV, Meakins JL. Neutrophil function in surgical patients: two inhibitors of granulocyte chemotaxis associated with sepsis. J Surg Res. 1979;26:355-64.
84. Abraham E, Chang YH. Cellular and humoral bases of hemorrhage-induced depression of lymphocyte function. Crit Care Med. 1986;14:81-6.
85. Constantian MB, Menzoian JO, Nimberg RB, Schmid K, Mannick JA. Association of a circulating immunosuppressive polypeptide with operative and accidental trauma. Ann Surg. 1977;185:73-9.
86. Bober LA, Grace MJ, Pugllese-Sivo C, Rojas-Triana A, Waters T, Sullivan LM, et al. The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacology. 1995;29:111-9
87. Szabo G, Kodys K, Miller-Graziano CL. Elevated monocyte interleukin-6 (IL-6) production in immunosuppressed trauma patients. I. Role of FcgRI cross-linking stimulation. J Clin Immunol. 1991;11:326-35.
88. Szabo G, Kodys K, Miller-Graziano CL. Elevated monocyte interleukin-6 (IL-6) production in immunosuppressed trauma patients. II. Downregulation by IL-4. J Clin Invest. 1991;11:336-44.
89. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993;103:565-75.
90. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993;21:318-27.
91. Dofferhoff AS, Bom VJ, de Vries-Hospers HG, van Ingen J, v.d. Meer J, Hazenberg BP, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med. 1992;20:185-92.
92. Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology. 1991; 101:782-5.
93. Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA. Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med. 1992;20:1414-9.
94. Marano MA, Fong Y, Moldawer LL, Wei H, Calvano SE, Tracey KJ, et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet. 1990;170: 32-8.
95. Pos O, van der Stelt ME, Wolbink GJ, Nijsten MW, van der Tempel GL, van Dijk W. Changes in the serum concentration and the glycosylation of human alpha 1-acid glycoprotein and alpha 1-protease inhibitor in severely burned persons: relation to interleukin-6 levels. Clin Exp Immunol. 1990;82:579-82.
96. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun. 1995;63:2109-12.
97. McCabe WR, Jackson GG. Gram-negative bacteremia. I: etiology and ecology. Ann Intern Med. 1962;110:847-53
98. Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA. 1995;274:338-45.
99. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;74:968-74.
100. Haire WD, Ruby EI, Gordon BG, Patil KD, Stephens LC, Kotulak GD, et al. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA. 1995;274:1289-95.
101. Bruserud O, Nesthus I, Buhring HJ, Pawelec G. Cytokine modulation of interleukin 1 and tumor necrosis factor-alpha secretion from acute myelogenous leukaemia blast cells in vitro. Leuk Res. 1995;19:15-22.